The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes

被引：31

作者：

Choe, Eun Yeong ^{[1
]}

Cho, Yongin ^{[1
]}

Choi, Younjeong ^{[1
]}

Yun, Yujung ^{[1
]}

Wang, Hye Jin ^{[2
]}

Kwon, Obin ^{[1
,2
,3
]}

Lee, Byung-Wan ^{[1
]}

Ahn, Chul Woo ^{[1
,4
]}

Cha, Bong Soo ^{[1
,2
,4
]}

Lee, Hyun Chul ^{[1
,4
]}

Kang, Eun Seok ^{[1
,2
,4
]}

机构：

[1] Yonsei Univ, Coll Med, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea

[2] Yonsei Univ, Coll Med, Brain Korea 21 Plus Project Med Sci, Seoul, South Korea

[3] Yonsei Univ, Coll Med, Dept Pharmacol, Seoul, South Korea

[4] Yonsei Univ, Coll Med, Inst Endocrine Res, Seoul, South Korea

来源：

DIABETES & METABOLISM JOURNAL | 2014年 / 38卷 / 03期

关键词：

Diabetes mellitus; DPP-4; inhibitor; Glycated serum albumin; Lipids;

D O I：

10.4093/dmj.2014.38.3.211

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: We evaluated the effects of two dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and vildagliptin, on metabolic parameters in patients with type 2 diabetes mellitus. Methods: A total of 170 type 2 diabetes patients treated with sitagliptin or vildagliptin for more than 24 weeks were selected. The patients were separated into two groups, sitagliptin (100 mg once daily, n=93) and vildagliptin ( 50 mg twice daily, n=77). We compared the effect of each DPP-4 inhibitor on metabolic parameters, including the fasting plasma glucose (FPG), postprandial glucose (PPG), glycated hemoglobin (HbA1c), and glycated albumin (GA) levels, and lipid parameters at baseline and after 24 weeks of treatment. Results: The HbA1c, FPG, and GA levels were similar between the two groups at baseline, but the sitagliptin group displayed a higher PPG level (P=0.03). After 24 weeks of treatment, all of the glucose-related parameters were significantly decreased in both groups (P=0.001). The levels of total cholesterol and triglycerides were only reduced in the vildagliptin group (P=0.001), although the sitagliptin group received a larger quantity of statins than the vildagliptin group (P=0.002). The mean change in the glucose-and lipid-related parameters after 24 weeks of treatment were not significantly different between the two groups (P=not significant). Neither sitagliptin nor vildagliptin treatment was associated with a reduction in the high sensitive C-reactive protein level (P=0.714). Conclusion: Vildagliptin and sitagliptin exert a similar effect on metabolic parameters, but vildagliptin exerts a more potent beneficial effect on lipid parameters.

引用

页码：211 / 219

页数：9

共 33 条

[1]

Chen L., Magliano D.J., Zimmet P.Z., The worldwide epidemiology of type 2 diabetes mellitus: present and future perspectives, Nat Rev Endocrinol, 8, pp. 228-236, (2012)

[2]

Ginter E., Simko V., Diabetes type 2 pandemic in 21st century, Bratisl Lek Listy, 111, pp. 134-137, (2010)

[3]

Fox C.S., Coady S., Sorlie P.D., D'Agostino Sr. R.B., Pencina M.J., Vasan R.S., Meigs J.B., Levy D., Savage P.J., Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study, Circulation, 115, pp. 1544-1550, (2007)

[4]

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, pp. 837-853, (1998)

[5]

Zoungas S., Patel A., Chalmers J., de Galan B.E., Li Q., Billot L., Woodward M., Ninomiya T., Neal B., MacMahon S., Grobbee D.E., Kengne A.P., Marre M., Heller S., Severe hypoglycemia and risks of vascular events and death, N Engl J Med, 363, pp. 1410-1418, (2010)

[6]

Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., Marre M., Cooper M., Glasziou P., Grobbee D., Hamet P., Harrap S., Heller S., Liu L., Mancia G., Mogensen C.E., Pan C., Poulter N., Rodgers A., Williams B., Bompoint S., de Galan B.E., Joshi R., Travert F., Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, N Engl J Med, 358, pp. 2560-2572, (2008)

[7]

Gerstein H.C., Miller M.E., Genuth S., Ismail-Beigi F., Buse J.B., Goff Jr. D.C., Probstfield J.L., Cushman W.C., Ginsberg H.N., Bigger J.T., Grimm Jr. R.H., Byington R.P., Rosenberg Y.D., Friedewald W.T., Long-term effects of intensive glucose lowering on cardiovascular outcomes, N Engl J Med, 364, pp. 818-828, (2011)

[8]

Barzilai N., Guo H., Mahoney E.M., Caporossi S., Golm G.T., Langdon R.B., Williams-Herman D., Kaufman K.D., Amatruda J.M., Goldstein B.J., Steinberg H., Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial, Curr Med Res Opin, 27, pp. 1049-1058, (2011)

[9]

Iwamoto Y., Taniguchi T., Nonaka K., Okamoto T., Okuyama K., Arjona Ferreira J.C., Amatruda J., Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus, Endocr J, 57, pp. 383-394, (2010)

[10]

Kim S.A., Shim W.H., Lee E.H., Lee Y.M., Beom S.H., Kim E.S., Yoo J.S., Nam J.S., Cho M.H., Park J.S., Ahn C.W., Kim K.R., Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus, Diabetes Metab J, 35, pp. 159-165, (2011)

← 1 2 3 4 →